Breaking News, Collaborations & Alliances

Gilead, J&J Unit To Develop HIV Combo-Drug

Gilead Sciences and Tibotec Pharmaceuticals, a unit of Johnson & Johnson, have entered an agreement to develop and commercialize a new fixed-dose combination of Truvada and TMC278 (rilpivirine).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Gilead Sciences and Tibotec Pharmaceuticals, a unit of Johnson & Johnson, have entered an agreement to develop and commercialize a new fixed-dose combination of Truvada and TMC278 (rilpivirine). Gilead will assume the lead role in the manufacturing, registration, distribution and commercialization of the fixed-dose combination drug worldwide, excluding the developing world and Japan. Tibotec will be responsible for the commercialization of rilpivirine as a stand-alone product and will hol...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters